Skip to main content

Chronic Rhinosinusitis With Nasal Polyps

7
Pipeline Programs
14
Companies
13
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
3
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 13 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Fortrea
FortreaDURHAM, NC
1 program
1
TezepelumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06706817Recruiting180Est. Jan 2027
Keymed Biosciences
Keymed BiosciencesChina - Chengdu
3 programs
1
2
CM310Phase 21 trial
CM326Phase 21 trial
CM326Phase 1/21 trial
Active Trials
NCT05324137Completed88Est. Mar 2024
NCT05131464Completed46Est. Jan 2024
NCT06372678Not Yet Recruiting90Est. Jun 2026
Biocorp
BiocorpFrance - Issoire
1 program
1
VerekitugPhase 21 trial
Active Trials
NCT06164704Completed81Est. Jul 2025
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
MepolizumabPhase 1Monoclonal Antibody
Trellis Bioscience
Trellis BioscienceCA - Redwood City
1 program
1
TRL1068Phase 11 trial
Active Trials
NCT05355207Unknown12Est. Jan 2025
Regeneron
RegeneronTARRYTOWN, NY
4 programs
ItepekimabPHASE_3Monoclonal Antibody
ItepekimabPHASE_3Monoclonal Antibody
ItepekimabPHASE_3Monoclonal Antibody
Dupilumab SAR231893PHASE_4
Sanofi
SanofiPARIS, France
2 programs
lunsekimigPHASE_22 trials
Dupilumab SAR231893PHASE_41 trial
Active Trials
NCT06914908Recruiting64Est. Jan 2031
NCT06609239Recruiting900Est. Jan 2031
NCT05049122Completed25Est. Jul 2023
Airway Therapeutics
Airway TherapeuticsGA - Marietta
1 program
Biologic drugsN/A
Sandoz
SandozAustria - Kundl
1 program
XolairN/A1 trial
Active Trials
NCT05626257Completed135Est. Apr 2025
GSK
GSKLONDON, United Kingdom
1 program
MepolizumabPHASE_1Monoclonal Antibody1 trial
Active Trials
NCT05895929Recruiting8Est. Jun 2026
Chia Tai TianQing Pharmaceutical Group
1 program
210mg of TQC2731 injectionPHASE_21 trial
Active Trials
NCT06451640Completed59Est. Oct 2025
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
CBP-201PHASE_21 trial
Active Trials
NCT04783389Terminated40Est. Jun 2022
Upstream Bio
Upstream BioWALTHAM, MA
1 program
VerekitugPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SanofiDupilumab SAR231893
FortreaTezepelumab
Sanofilunsekimig
Sanofilunsekimig
Chia Tai TianQing Pharmaceutical Group210mg of TQC2731 injection
Keymed BiosciencesCM326
BiocorpVerekitug
Keymed BiosciencesCM310
Connect BiopharmaCBP-201
Keymed BiosciencesCM326
Trellis BioscienceTRL1068
GSKMepolizumab
SandozXolair

Clinical Trials (13)

Total enrollment: 1,728 patients across 13 trials

NCT05049122SanofiDupilumab SAR231893

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

Start: Oct 2021Est. completion: Jul 202325 patients
Phase 4Completed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

Start: Dec 2024Est. completion: Jan 2027180 patients
Phase 3Recruiting

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

Start: May 2025Est. completion: Jan 203164 patients
Phase 2Recruiting

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.

Start: Sep 2024Est. completion: Jan 2031900 patients
Phase 2Recruiting

A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Start: Jul 2024Est. completion: Oct 202559 patients
Phase 2Completed

Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Start: Jun 2024Est. completion: Jun 202690 patients
Phase 2Not Yet Recruiting

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Start: Dec 2023Est. completion: Jul 202581 patients
Phase 2Completed

The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Start: Nov 2021Est. completion: Jan 202446 patients
Phase 2Completed

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Start: Jun 2021Est. completion: Jun 202240 patients
Phase 2Terminated

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Start: Jul 2022Est. completion: Mar 202488 patients
Phase 1/2Completed

Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis

Start: Jan 2024Est. completion: Jan 202512 patients
Phase 1Unknown
NCT05895929GSKMepolizumab

The Role of IL5 in Epithelial Cell Integrity

Start: Sep 2023Est. completion: Jun 20268 patients
Phase 1Recruiting

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

Start: Jan 2023Est. completion: Apr 2025135 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 1,728 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.